Novartis ‘Urgently’ Working To Improve Zolgensma Access Program
‘Lottery-Style’ Scheme Has Gone Down Better Outside Europe
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
If Zolgensma gets the thumbs up from the EMA this week, it will likely get formal EU approval within a couple of months.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.